MEET THE TEAM
LINYA WANG, PH.D.
Dr. Wang is a microbiologist and cell biologist. She received her Ph.D. in Microbiology at National Taiwan University College of Medicine, and worked in Institute of Molecular Biology at Academia Sinica, Taiwan. She then finished her postdoctoral training in Molecular Microbiology and Immunology at University of Southern California, USA. Linya has switched from academic to industrial field. She is now working in AbVision inc., which focuses on therapeutic antibody drug discovery that can be applied to immunotherapy, cell therapy, and target therapy. She has also been involved in National Taiwan University Alumni Association as the President of Young Professional Group, Taiwanese Junior Chamber of Commerce as the Board of Director, Nextcon innovation startup as the organizer, and Southern California Taiwanese Biotechnology Association as the President.
MIN-SHAN CHEN, PH.D.
Dr. Chen is a sales and business development manager at RevMAb Biosciences. Prior to her current role, she is a consultant in product development at Tessa Therapeutics. She finished an internship in life science development at Fannin Innovation Studio during her Ph.D. She received a Ph.D. in Biomedical Science from Baylor College of Medicine with specialized training in cancer and stem cell biology and a Master of Science from National Taiwan University. She has been involved in Texas Taiwanese Biotechnology Association as the Vice President.
CHIH-CHAO YANG, PH.D.
Chih-Chao currently works as a scientist in the cell culture group at Bionova Scientific, working on upstream bioreactors for antibody and viral productions. He earned his Ph.D. degree in biomedical Sciences from The University of Texas Health Science Center at Houston, where he focused his research on tumor-related signaling pathways in both Drosophila and mammals. He then moved to Vanderbilt University School of Medicine for his postdoctoral training, utilizing CRISPR/Cas9 technologies to investigate the roles of cell polarity proteins in cell growth and cell survival.
MU-EN (DAVID) LIN, PH.D.
Dr. Lin is an early discovery scientist at RevMAb Biosciences, where he focused on lead generation, characterization, validation, and optimization on several programs within the immune-modulating and oncology field. Prior to this role, Dr. Lin has been trained in both neuro- and cardiovascular- diseases in The Scripps Research Institute and the University of Washington. With a keen interest in various disease models, he is always looking for opportunities to bridge science and clinical treatments. Dr. Lin received his Ph.D. in Biomedical Sciences, University of California, San Diego.
KAI YANG, M.S., M.B.A.
Kai Yang is a senior product manager at Thermo Fisher Scientific, focusing on sequencing products. Kai has vast experience in genetic analysis marketing field, as well as experience in consulting, project management, operation, quality and research and development. Prior to her current role, Kai was a marketing consultant in biotech and pharmaceutical industry. She holds a master of science degree from Johns Hopkins University and a M.B.A degree from Haas School of Business, UC Berkeley.
ERIC DU, M.P.H., M.B.A.
Eric Du is a project manager at Gilead Sciences, responsible for strategic planning, execution, and delivery of various operational efficiency-related initiatives as well as organizational change management within R&D. Prior to his current role, he has worked as a public health consultant servicing CDC and State-level health departments. He is also the managing director of Formosan Enterprise Institute (FEI), with a special focus on biotechnology & defense sectors. Eric holds an MBA degree from Georgetown University, and an MPH from Emory University.
MING-CHI TSAI, PH.D.
Board member and web master
Dr. Tsai is a neuroscientist at Genentech. Prior to his current role, he was a assistant project scientist developing neurotechnology to understand brain function and as future therapeutics at UC Berkeley. He received his PhD in Neurophysiology from Univ. of Alabama at Birmingham and MSc in Neuroscience from University College London.
CHENG-CHIU HUANG, PH.D.
Event Organizer (Founding Member/Past President)
Cheng-Chiu is the Director of Portfolio and Pipeline Management at Ansun Biopharma. He received his postdoctoral training in neural circuit formation and peripheral neuropathy from HHMI-Janelia Research Campus and Washington University in St. Louis, after getting his Ph.D. from Baylor College of Medicine. Before joining Ansun, Cheng-Chiu worked at Merck and TLC Biopharmaceuticals. Cheng-Chiu is passionate about drug discovery, corporate development, science communication, as well as amateur volleyball games.
CHING-SHIN HUANG, PH.D.
Dr. Huang is a postdoctoral fellow in the molecular engineering group of Amgen at South San Francisco. He currently utilizes biophysics techniques, including X-ray crystallography and Cryo-EM, for epitope mapping of antibody-antigen interactions and resolving the binding interfaces between ligands/drugs and receptor proteins. Before coming to the Bay area, He received his Ph. D. degree in molecular biophysics from New York University, where he determined the structure of a membrane protein complex by X-ray crystallography.
BRAD LIN, M.S.
Brad Lin is a business development manager at Wiltrom, a spinal medical device company in San Jose. Prior to his current role, Brad obtained clinical knowledge of medical devices through serving as clinical marketing specialist at Siemens Healthineers and knowledge of automation system development at National Instruments. Brad received his master’s degree in biomedical engineering from National Cheng Kung University and bachelor’s degree in electrical engineering from National Taiwan University of Science and Technology.
PAST BOARD MEMBERS
JUNG-TING (BOB) CHIEN, PH.D.
Founding Member (Director of Public Relationship)
Dr. Chien is now the CEO and founder of Marigen Inc. Dr. Chien has extensive knowledge of A.I., machine learning, bioinformatics, biotechnology, and clinical diagnostic technology. Prior to current roles, Dr. Chien founded a sequencing service company and worked at Bayer AG and ThermoFisher Scientific. Dr. Chien also serves on the advisory board for start-up companies and SlingHealth incubator as well as a board member of Formosa Enterprise Institute and Bay Area Taiwanese Biotechnology Association. Dr. Chien received his Ph.D. in computer science and M.S. in data science from Emory University and his B.S. in medical technology from China Medical University, Taiwan.
SHANN-CHING CHEN, PH.D.
Dr. Chen is a dedicated, versatile machine learning scientist with extensive industrial and academic experience in biomedical data analysis, including medical images and high throughput genomics. Specialties: Deep Learning, Image Analysis, and Next Generation Sequencing.
CHIA-HSIANG (SEAN) HSUEH, PH.D.
Dr. Hsueh is a clinical pharmacologist at Gilead Science, supporting inflammatory, oncology, hepatitis C (HCV) and nonalcoholic steatohepatitis (NASH) programs. Prior to Gilead, he was an Oak Ridge Institute for Science Education (ORISE) fellow at the US Food and Drug Administration (FDA). He received his PHD (pharmacology) and BS (pharmacy) in National Taiwan University.
LIN LIN, RN, PH.D.
Dr. Lin is a professor at UCSF. She is currently leading the Epigenome Interaction and Gene Regulation in Uterine Myometrium study at UCSF, School of Nursing. She is also the Assistant Director of the Masters Entry Program in Nursing. Dr. Lin received her Ph.D. from the University of North Carolina-Chapel Hill.
YUAN-HUNG LO, PH.D.
Dr. Lo is an NIH/NCI K00 Postdoctoral Fellow at Stanford University. He is currently working on several projects to understand the control of gastrointestinal and cancer stem cell biology. By applying powerful next-generation CRISPR/Cas9 genome editing tools, primary 3D human organoids culture system and state-of-the-art transgenic mouse models, Dr. Lo has focused his efforts on gaining insight into how critical intrinsic genetic mutations and extrinsic extracellular signals within the microenvironment can contribute to gastrointestinal stem cell activity and tumorigenesis. Dr. Lo holds a Ph.D. degree in cancer and stem cell biology from Baylor College of Medicine, and a M.S. degree in molecular and cellular biology from National Tsing Hua Univerisy, Taiwan.
Experienced Associate Research Manager with a demonstrated history of working in the biotechnology industry. Skilled in Statistical Data Analysis, Molecular Biology, Management, Cell Culture, and Molecular & Cellular Biology. Strong business development professional with a Master’s Degree focused in Neuroscience from National Taiwan University.